S
Susan Lindquist
Researcher at Massachusetts Institute of Technology
Publications - 443
Citations - 86482
Susan Lindquist is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Heat shock protein & Saccharomyces cerevisiae. The author has an hindex of 147, co-authored 440 publications receiving 81067 citations. Previous affiliations of Susan Lindquist include University of Illinois at Chicago & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Alternative assembly pathways of the amyloidogenic yeast prion determinant Sup35–NM
TL;DR: An alternative assembly pathway of NM is described that produces filaments that are composed of β‐strands and random coiled regions with several‐fold smaller diameters than the amyloid fibres.
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity
Susan Lindquist,Steve Henikoff +1 more
Journal ArticleDOI
A chaperone pathway in protein disaggregation: Hsp26 ALTERS THE NATURE OF PROTEIN AGGREGATES TO FACILITATE REACTIVATION BY Hsp104. VOLUME 280 (2005) PAGES 23869-23875
Journal ArticleDOI
Inhibiting mitochondrial phosphate transport as an unexploited antifungal strategy.
Catherine A. McLellan,Benjamin Vincent,Norma V. Solis,Alex K. Lancaster,Lucas B. Sullivan,Cathy L Hartland,Willmen Youngsaye,Scott G. Filler,Scott G. Filler,Luke Whitesell,Susan Lindquist +10 more
TL;DR: Mechanistic characterization of ML316, a thiohydantoin which kills drug-resistant Candida species at nanomolar concentrations through fungal-selective inhibition of the mitochondrial phosphate carrier Mir1, is reported, establishing ML316 as the first Mir1 inhibitor using genetic, biochemical, and metabolomic approaches.
Journal ArticleDOI
From yeast to patient neurons and back again: Powerful new discovery platforms
Daniel F. Tardiff,Vikram Khurana,Vikram Khurana,Chee Yeun Chung,Susan Lindquist,Susan Lindquist +5 more
TL;DR: Two recent reports are described that together establish yeast‐to‐human discovery platforms for synucleinopathies, where genes and small molecules identified in yeast were validated in patient‐derived neurons that present the same cellular phenotypes initially discovered in yeast.